Table 1 Pre-treatment clinical characteristics and duration of ADT in the pT0 and non-pT0 groups
pT0 (N = 24) | non-pT0 (N = 44) | p value | |
|---|---|---|---|
Age, yr | |||
Median | 67 | 69 | 0.25 |
Range | 56-76 | 54-75 | |
PSA level, ng/ml | |||
Median | 10 | 11.3 | 0.261 |
Range | 4.8-29.0 | 4.9-73.9 | |
Clinical stage (%) | |||
T1c | 8 (33.3) | 16 (36.4) | 0.865 |
T2a | 10 (41.7) | 18 (40.9) | |
T2b | 3 (12.5) | 7 (15.9) | |
T2c | 3 (12.5) | 3 (6.8) | |
Gleason score (%) | |||
≤ 6 | 7 (29.2) | 12 (27.3) | 0.227 |
7 | 11 (70.8) | 27 (61.4) | |
≥ 8 | 0 (0.0) | 5 (11.4) | |
Risk* (%) | |||
Low | 4 (16.7) | 9 (20.5) | 0.887 |
Intermediate | 10 (41.7) | 16 (36.4) | |
High | 10 (41.7) | 19 (43.2) | |
Duration of ADT, mo | |||
Median | 9 | 7.5 | 0.022 |
Range | 3-19 | 3-29 | |
n PSA before PRx ** (%) | |||
< 0.2 ng/ml | 24 (100) | 39 (88.6) | 0.219 |
> 0.2 ng/ml | 0 | 5 (11.4) |